Literature DB >> 23956430

Contributions of the three CYP1 monooxygenases to pro-inflammatory and inflammation-resolution lipid mediator pathways.

Senad Divanovic1, Jesmond Dalli2, Lucia F Jorge-Nebert3, Christopher L Karp1, Charles N Serhan2, Daniel W Nebert3, Leah M Flick1, Marina Gálvez-Peralta3, Nicholas D Boespflug1, Traci E Stankiewicz1, Jonathan M Fitzgerald2, Maheshika Somarathna3.   

Abstract

All three cytochrome P450 1 (CYP1) monooxygenases are believed to participate in lipid mediator biosynthesis and/or their local inactivation; however, distinct metabolic steps are unknown. We used multiple-reaction monitoring and liquid chromatography-UV coupled with tandem mass spectrometry-based lipid-mediator metabololipidomics to identify and quantify three lipid-mediator metabolomes in basal peritoneal and zymosan-stimulated inflammatory exudates, comparing Cyp1a1/1a2/1b1(⁻/⁻) C57BL/6J-background triple-knockout mice with C57BL/6J wild-type mice. Significant differences between untreated triple-knockout and wild-type mice were not found for peritoneal cell number or type or for basal CYP1 activities involving 11 identified metabolic steps. Following zymosan-initiated inflammation, 18 lipid mediators were identified, including members of the eicosanoids and specialized proresolving mediators (i.e., resolvins and protectins). Compared with wild-type mice, Cyp1 triple-knockout mice exhibited increased neutrophil recruitment in zymosan-treated peritoneal exudates. Zymosan stimulation was associated with eight statistically significantly altered metabolic steps: increased arachidonic acid-derived leukotriene B₄ (LTB₄) and decreased 5S-hydroxyeicosatetraenoic acid; decreased docosahexaenoic acid-derived neuroprotectin D1/protectin D1, 17S-hydroxydocosahexaenoic acid, and 14S-hydroxydocosahexaenoic acid; and decreased eicosapentaenoic acid-derived 18R-hydroxyeicosapentaenoic acid (HEPE), 15S-HEPE, and 12S-HEPE. In neutrophils analyzed ex vivo, elevated LTB₄ levels were shown to parallel increased neutrophil numbers, and 20-hydroxy-LTB₄ formation was found to be deficient in Cyp1 triple-knockout mice. Together, these results demonstrate novel contributions of CYP1 enzymes to the local metabolite profile of lipid mediators that regulate neutrophilic inflammation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23956430      PMCID: PMC3810452          DOI: 10.4049/jimmunol.1300699

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

Review 1.  Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators.

Authors:  Eric L Campbell; Charles N Serhan; Sean P Colgan
Journal:  J Immunol       Date:  2011-10-01       Impact factor: 5.422

Review 2.  Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?

Authors:  Charles N Serhan
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

3.  The small Rho GTPase Cdc42 regulates neutrophil polarity via CD11b integrin signaling.

Authors:  Kathleen Szczur; Yi Zheng; Marie-Dominique Filippi
Journal:  Blood       Date:  2009-09-14       Impact factor: 22.113

4.  Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation.

Authors:  Sungwhan F Oh; Padmini S Pillai; Antonio Recchiuti; Rong Yang; Charles N Serhan
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 14.808

5.  Novel proresolving aspirin-triggered DHA pathway.

Authors:  Charles N Serhan; Gabrielle Fredman; Rong Yang; Sergey Karamnov; Ludmila S Belayev; Nicolas G Bazan; Min Zhu; Jeremy W Winkler; Nicos A Petasis
Journal:  Chem Biol       Date:  2011-08-26

Review 6.  Resolvins and protectins in inflammation resolution.

Authors:  Charles N Serhan; Nicos A Petasis
Journal:  Chem Rev       Date:  2011-07-18       Impact factor: 60.622

7.  Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line.

Authors:  Maki Hasegawa; Yury Kapelyukh; Harunobu Tahara; Jost Seibler; Anja Rode; Sylvia Krueger; Dongtao N Lee; C Roland Wolf; Nico Scheer
Journal:  Mol Pharmacol       Date:  2011-05-31       Impact factor: 4.436

Review 8.  Endogenous and exogenous ligands of aryl hydrocarbon receptor: current state of art.

Authors:  Lucie Stejskalova; Zdenek Dvorak; Petr Pavek
Journal:  Curr Drug Metab       Date:  2011-02       Impact factor: 3.731

9.  Inbreeding and epigenetics: beneficial as well as deleterious effects.

Authors:  Daniel W Nebert; Marina Gálvez-Peralta; Zhanquan Shi; Nadine Dragin
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

10.  Increased blood pressure in mice lacking cytochrome P450 2J5.

Authors:  Krairerk Athirakul; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Jixiang Ma; Yun Zhao; John F Couse; Raymond Quigley; David R Harder; Xueying Zhao; John D Imig; Theresa L Pedersen; John W Newman; Bruce D Hammock; Alan J Conley; Kenneth S Korach; Thomas M Coffman; Darryl C Zeldin
Journal:  FASEB J       Date:  2008-08-20       Impact factor: 5.191

View more
  19 in total

1.  Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles: Correlations With Survival and Clinical Outcomes.

Authors:  Jesmond Dalli; Romain A Colas; Carolina Quintana; Diana Barragan-Bradford; Shelley Hurwitz; Bruce D Levy; Augustine M Choi; Charles N Serhan; Rebecca M Baron
Journal:  Crit Care Med       Date:  2017-01       Impact factor: 7.598

2.  The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide.

Authors:  Jesmond Dalli; Bryan D Kraft; Romain A Colas; Masakazu Shinohara; Laura E Fredenburgh; Dean R Hess; Nan Chiang; Karen Welty-Wolf; Augustine M Choi; Claude A Piantadosi; Charles N Serhan
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

Review 3.  The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.

Authors:  Charles N Serhan; Nan Chiang; Jesmond Dalli
Journal:  Semin Immunol       Date:  2015-04-07       Impact factor: 11.130

Review 4.  Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases.

Authors:  Nandini Krishnamoorthy; Raja-Elie E Abdulnour; Katherine H Walker; Braden D Engstrom; Bruce D Levy
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

5.  Acute injection of a DHA triglyceride emulsion after hypoxic-ischemic brain injury in mice increases both DHA and EPA levels in blood and brain.

Authors:  Denny Joseph Manual Kollareth; Richard J Deckelbaum; Zequn Liu; Rajasekhar Ramakrishnan; Charlotte Jouvene; Charles N Serhan; Vadim S Ten; Hylde Zirpoli
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2020-09-25       Impact factor: 4.006

6.  Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity.

Authors:  Aarti Asnani; Baohui Zheng; Yan Liu; You Wang; Howard H Chen; Anita Vohra; An Chi; Ivan Cornella-Taracido; Huijun Wang; Douglas G Johns; David E Sosnovik; Randall T Peterson
Journal:  JCI Insight       Date:  2018-01-11

Review 7.  Aryl hydrocarbon receptor (AHR): "pioneer member" of the basic-helix/loop/helix per-Arnt-sim (bHLH/PAS) family of "sensors" of foreign and endogenous signals.

Authors:  Daniel W Nebert
Journal:  Prog Lipid Res       Date:  2017-06-09       Impact factor: 16.195

8.  Mice deficient in the gene for cytochrome P450 (CYP)1A1 are more susceptible than wild-type to hyperoxic lung injury: evidence for protective role of CYP1A1 against oxidative stress.

Authors:  Krithika Lingappan; Weiwu Jiang; Lihua Wang; Gangduo Wang; Xanthi I Couroucli; Binoy Shivanna; Stephen E Welty; Roberto Barrios; M Firoze Khan; Daniel W Nebert; L Jackson Roberts; Bhagavatula Moorthy
Journal:  Toxicol Sci       Date:  2014-06-03       Impact factor: 4.849

9.  Structure-Based Design and Synthesis of New Estrane-Pyridine Derivatives as Cytochrome P450 (CYP) 1B1 Inhibitors.

Authors:  Raphaël Dutour; Francisco Cortés-Benítez; Jenny Roy; Donald Poirier
Journal:  ACS Med Chem Lett       Date:  2017-10-11       Impact factor: 4.345

10.  Commercial scale production of RvD4 opens the resolving door to new research.

Authors:  Matthew L Edin; Darryl C Zeldin
Journal:  J Leukoc Biol       Date:  2018-03-30       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.